Terumo (OTCMKTS:TRUMY) Stock Price Crosses Below Fifty Day Moving Average - Here's Why

Key Points

• Terumo Corp. (OTCMKTS:TRUMY) shares fell below their 50-day moving average of $17.54, trading as low as $16.30 before closing at $16.34.
• The company reported a quarterly earnings per share of $0.20, exceeding expectations of $0.17, but fell short of revenue expectations with $1.76 billion against an anticipated $1.80 billion.
• Terumo has a market capitalization of $24.20 billion and a low debt-to-equity ratio of 0.07, indicating financial stability.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) shares crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $17.54 and traded as low as $16.30. Terumo shares last traded at $16.34, with a volume of 158,180 shares trading hands.

Terumo Stock Down 2.2%

The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.53 and a current ratio of 2.64. The stock has a market cap of $24.20 billion, a price-to-earnings ratio of 28.67 and a beta of 0.79. The firm's 50-day simple moving average is $17.54 and its two-hundred day simple moving average is $18.00.

Terumo (OTCMKTS:TRUMY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03. The firm had revenue of $1.76 billion during the quarter, compared to analysts' expectations of $1.80 billion. Terumo had a net margin of 12.09% and a return on equity of 9.19%.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.